Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

SP Antagonist Therapy

VM Vignayanandam Ravindernath-Jayashree Muddapu
KV Karthik Vijayakumar
KR Keerthiga Ramakrishnan
VC V. Srinivasa Chakravarthy
request Request a Protocol
ask Ask a question
Favorite

It was reported that SP exacerbated dopaminergic neurodegeneration in mice (Wang et al., 2014), and, therefore, administrating SP antagonists creates neuroprotection of dopaminergic neurons in PD (Thornton and Vink, 2012, 2015; Johnson et al., 2017). In the proposed LIT model, SP antagonist effect was implemented as,

where wsp is the influence of SP on wSTN→SNc, δspa is the proportion of SP inhibition, and wspa is the influence of SP on wSTN→SNc under SP antagonist therapy.

The SP antagonist therapy was implemented in the proposed LIT model by the following criterion,

where δspa(Nscz,t) is the instantaneous proportion of SP inhibition based on the number of surviving SNc neurons or terminals at the time (t)(Nscz(t)), δspamed is the proportion of SP inhibition during therapy, Nscz (t) is the instantaneous number of surviving SNc neurons or terminals, and  Tlz represents the number of surviving SNc cells or terminals at which therapeutic intervention was employed (z = soma or terminal).

Copyright and License information:  ©2022 Muddapu, Vijayakumar, Ramakrishnan and Chakravarthy.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A